OraSure Technologies, Inc. (NASDAQ:OSUR) SVP Jack E. Jerrett sold 73,463 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.77, for a total transaction of $1,525,826.51. Following the completion of the sale, the senior vice president now owns 81,593 shares of the company’s stock, valued at approximately $1,694,686.61. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

OraSure Technologies, Inc. (NASDAQ OSUR) traded up 1.23% during midday trading on Tuesday, reaching $21.46. 1,088,278 shares of the company’s stock were exchanged. The stock has a market cap of $1.25 billion, a P/E ratio of 39.67 and a beta of 1.57. The firm’s 50-day moving average is $17.63 and its 200 day moving average is $13.64. OraSure Technologies, Inc. has a 1-year low of $6.84 and a 1-year high of $21.55.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same period in the prior year, the firm posted $0.07 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. Equities analysts anticipate that OraSure Technologies, Inc. will post $0.48 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: OraSure Technologies, Inc. (OSUR) SVP Sells 73,463 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/insider-selling-orasure-technologies-inc-osur-svp-sells-73463-shares-of-stock.html.

A number of hedge funds have recently bought and sold shares of the company. First Mercantile Trust Co. purchased a new stake in OraSure Technologies during the second quarter valued at about $104,000. Victory Capital Management Inc. purchased a new stake in OraSure Technologies during the first quarter valued at about $100,000. Profund Advisors LLC purchased a new stake in OraSure Technologies during the first quarter valued at about $137,000. BNP Paribas Arbitrage SA raised its stake in OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock valued at $139,000 after buying an additional 9,723 shares during the period. Finally, Private Advisor Group LLC raised its stake in OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 723 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on OSUR shares. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Saturday, May 6th. Jefferies Group LLC increased their target price on shares of OraSure Technologies from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 4th. Canaccord Genuity increased their target price on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Stephens reiterated an “overweight” rating and issued a $19.00 target price (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Finally, BidaskClub downgraded shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $15.46.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.